Cerebral venous thrombosis and activated protein C resistance

Stroke

Volumn 27, Issue 10, 1996, Pages 1731-1733

  Dulli, Douglas A ^a   Luzzio, Christopher C ^a   Williams, Eliot C ^a   Schutta, Henry S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

cerebral embolism and thrombosis; contraceptives, oral; protein C; protein S deficiency; sinus thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; HEPARIN; ORAL CONTRACEPTIVE AGENT; WARFARIN;

ADULT; ARTICLE; CASE REPORT; CAVERNOUS SINUS THROMBOSIS; FAMILY HISTORY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; OCCLUSIVE CEREBROVASCULAR DISEASE; ORAL CONTRACEPTION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RISK FACTOR; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 0029768069     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.27.10.1731     Document Type: Article

References (16)

1. Bousser MG, Barnett HJM. Cerebral venous thrombosis. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM, eds. Stroke: Pathophysiology, Diagnosis, and Management. 2nd ed. New York, NY: Churchill Livingstone Inc; 1992.
2. Schutta HS. Cerebral venous thrombosis. In: Joynt RJ, Ed. Clinical Neurology. Philadelphia, Pa: JB Lippincott; 1991.
3. (506) to Gln Mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost. 1995;74:139-148.
4. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994; 6:2521-2524.
5. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-522.
6. Voelkerding KV, Wu L, Williams EC, Huffman SM, Sabatini LM, Borcherding WR, Huber S. Factor V R506Q gene mutation analysis by PCR-RLF: optimization, comparison with functional testing for resistance to activated protein C, and establishment of cell line controls. J Clin Pathol. 1996;106:100-106.
7. Trossaërtt M, Conard J, Horellou MH, Samama MM, Ireland H, Bayston TA, Lane DA. Modified APC resistance assay for patients on oral anticoagulants. Lancet. 1994,344:1709.
8. Bridey F, Wolf M, Laissy JP, Morin V, Lefebvre M, de Prost S. Fatal cerebral venous thrombosis associated with the factor V Leiden mutation and the use of oral contraceptives. Thromb Haemost. 1995; 74:1379. Letter.
9. Martinelli I, Landi G, Merati O, Cella E, Tosetto A, Mannucci PM. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost. 1996;75:393-394.
10. Deschiens MA, Conard J, Horellou MH, Ameri A, Preter M, Chedru F, Samama MM, Bousser M-G. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke. 1996;27:1724-1730.
11. Zuber M, Toulon P, Marnet L, Mas J-L. Factor V Leiden mutation in cerebral venous thrombosis. Stroke. 1996;27:1721-1723.
12. Koster FR, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet. 1993; 342:1507-1506.
13. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden. Lancet. 1994;344:1453-1457.
14. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor Villa. J Biol Chem. 1994;269:18735-18738.
15. Siegert CEH, Smelt AHM, de Bruin TWA. Superior sagittal sinus thrombosis and thyrotoxicosis: possible association in two cases. Stroke. 1995;26:496-497.
16. De Stefano V, Finazzi G, Mannuci PM. Inherited thrombophilia: pathogenesis, clinical syndromes and management. Blood. 1996;87: 3531-3544.